(Q34500856)

English

High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

Cancer and Leukemia Group B

13

object named as

Cancer and Leukemia Group B

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

10

object named as

Guido Marcucci

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Richard A. Larson

12

object named as

Richard A Larson

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

11

object named as

David Hurd

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

author name string

Richard M Stone

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Barry Moser

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Ben Sanford

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Philip Schulman

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Jonathan E Kolitz

5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Steven Allen

6

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Wendy Stock

7

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Ilene Galinsky

8

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Ravi Vij

9

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

4 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Leukemia Research

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

35

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

329-333

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023007

7 July 2018

Anthracycline dose intensification in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023007

7 July 2018

Acute myelogenous leukemia in older adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023007

7 July 2018

Optimizing therapy for acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023007

7 July 2018

Incorporating hematopoietic cell transplantation (HCT) into the management of adults aged under 60 years with acute myeloid leukemia (AML).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023007

7 July 2018

Novel strategies for relapsed and refractory acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023007

7 July 2018

Acute myeloid leukemia and the position of autologous stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023007

7 July 2018

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023007

7 July 2018

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023007

7 July 2018

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023007

7 July 2018

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023007

7 July 2018

Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023007

7 July 2018

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023007

7 July 2018

Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023007

7 July 2018

High dose cytarabine: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023007

7 July 2018

The characteristics and outcome of patients with late relapse acute myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023007

7 July 2018

Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023007

27 October 2018

Auto-SCT for AML in second remission: CALGB study 9620.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023007

27 October 2018

Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023007

27 October 2018

Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023007

27 October 2018

Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023007

27 October 2018

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023007

27 October 2018

Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20688393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved survival for patients with acute myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20688393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult

1 reference

https://pubmed.ncbi.nlm.nih.gov/20688393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.LEUKRES.2010.07.017

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34500856&oldid=1782267378"